Press Release

Glythera and the FDA enter into vaccine research collaboration agreement

The FDA is to assess the feasibility of Glythera technology in developing antigenic glycoproteins as synthetic conjugate vaccines. Glythera Ltd, a UK based company specialising in developing an improved generation of biological therapeutics through advanced glycosylation technologies will collaborate with the US Food and Drug Administration (FDA) to assess the feasibility of applying Glythera's PermaLink™ technology to the generation of synthetic carbohydrate-based conjugate vaccines. The collaboration will examine the potential advantages of using Glythera's technology (PermaLink) for attaching synthetically made…

Read more>>

‹ First 

Page 11 of 11